文献速递认知障碍与痴呆

马来酸依多奈匹克治疗轻中度阿尔茨海默病的2期随机临床试验

Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2019-01-01

这项52周、52个中心的2期随机双盲安慰剂对照试验纳入484例轻中度阿尔茨海默病患者,比较马来酸依多奈匹克224 mg、448 mg与安慰剂的疗效与安全性。结果显示两种剂量在ADAS-cog和ADCS-CGIC上均未优于安慰剂,但安全性和耐受性可接受,胃肠道不良事件较多。

要点

  • 马来酸依多奈匹克224 mg和448 mg每日一次均未显著改善52周ADAS-cog评分。
  • ADCS-CGIC评分在各组间无显著差异,未显示临床整体获益。
  • 药物总体安全可耐受,但腹泻和呕吐常见,不良事件停药率高于安慰剂。

核心结论

  • 马来酸依多奈匹克在轻中度阿尔茨海默病患者中安全可耐受,但未显示临床疗效。

研究设计与样本

  • 随机、双盲、安慰剂对照、平行组2期临床试验,2014年6月2日至2016年12月14日在美国52个临床和学术中心进行52周。
  • 822例门诊患者筛查后484例随机分配,年龄55至85岁、 probable阿尔茨海默病、MMSE 12至22分、稳定服用多奈哌齐或利斯的明(可联用美金刚)。
  • 按1:1:1随机分配至安慰剂、马来酸依多奈匹克224 mg或448 mg,每日一次。

主要发现

  • 52周ADAS-cog评分平均变化:安慰剂组7.91,224 mg组7.45,448 mg组7.08。
  • 因不良事件停药:安慰剂组7/158(4.4%),224 mg组23/166(13.9%),448 mg组23/158(14.6%)。
  • 最常见不良事件为腹泻和呕吐。

临床怎么用

  • 该2期试验未提供马来酸依多奈匹克治疗轻中度阿尔茨海默病的疗效证据,不支持临床使用。
  • 用药期间需关注腹泻、呕吐等胃肠道不良事件及因不良事件停药风险。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Edonerpic maleate (T-817MA) protects against Aβ40-induced neurotoxic effects and memory deficits, promotes neurite outgrowth, and preserves hippocampal synapses and spatial memory in tau transgenic mice. These effects may be mediated via sigma-1 receptor activation, delivery of synaptic AMPA receptors, or modulation of microglial function and may benefit patients with Alzheimer disease. OBJECTIVE: To assess the efficacy, safety, and tolerability of edonerpic for patients with mild to moderate Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, parallel-group, phase 2 clinical trial conducted over 52 weeks from June 2, 2014, to December 14, 2016, at 52 US clinical and academic centers. Of 822 outpatients screened, 484 met the following criteria and were randomly assigned to treatment: 55 to 85 years of age, probable Alzheimer disease, Mini-Mental State Examination scores from 12 to 22, and taking stable doses of donepezil or rivastigmine with or without memantine. INTERVENTIONS: Random assignment (1:1:1 allocation) to placebo or 224 mg or 448 mg of edonerpic maleate, once per day. MAIN OUTCOMES AND MEASURES: Coprimary outcomes were scores on the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and Alzheimer's Disease Cooperative Study-Clinical Impression of Change (ADCS-CGIC) at week 52. Biomarkers were brain, lateral ventricular, and hippocampal volumes, as determined on magnetic resonance imaging, and cerebrospinal fluid Aβ40, Aβ42, total tau, and phospho-tau181. The primary efficacy analysis was performed on the coprimary end points for the modified intention-to-treat population. RESULTS: Of 482 participants in the safety population, 140 of 158 participants (88.6%) assigned to placebo, 117 of 166 participants (70.5%) to 224 mg of edonerpic maleate, and 120 of 158 participants (76.0%) to 448 mg of edonerpic maleate completed the trial. The mean ADAS-cog score change at week 52 was 7.91 for the placebo group, 7.45 for the 224-mg group, and 7.08 for the 448-mg group. Mean differences from placebo were -0.47 (95% CI, -2.36 to 1.43; P = .63) for the 224-mg group and -0.84 (95% CI, -2.75 to 1.08; P = .39) for the 448-mg group. Mean ADCS-CGIC scores were 5.22 for the placebo group, 5.24 for the 224-mg group, and 5.25 for the 448-mg group, with mean differences from placebo of 0.03 (95% CI, -0.20 to 0.25; P = .81) for the 224-mg group and 0.04 (95% CI, -0.19 to 0.26; P = .76) for the 448-mg group. In the safety population, a total of 7 of 158 participants (4.4%) in the placebo group, 23 of 166 participants (13.9%) in the 224-mg group, and 23 of 158 participants (14.6%) in the 448-mg group discontinued because of adverse events. The most frequent adverse events were diarrhea and vomiting. CONCLUSIONS AND RELEVANCE: Edonerpic maleate appeared to be safe and tolerable, with expected gastrointestinal symptoms occurring early but without evidence for a clinical effect among patients with mild to moderate Alzheimer disease. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02079909.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Schneider LS, Thomas RG, Hendrix S, et al. Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2019. PMID: 31282954. doi:10.1001/jamaneurol.2019.1868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。